MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
Clinical trials for MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS explained in plain language.
Never miss a new study
Get alerted when new MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS trials appear
Sign up with your email to follow new studies for MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Hope for rare kidney patients: new drug shows promise in phase 3 trial
Disease control CompletedThis study tested a drug called pegcetacoplan in 124 adults and teens with two rare kidney diseases (C3G and IC-MPGN). The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage, compared to a placebo. Participants received injections twice a week …
Matched conditions: MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 05:31 UTC
-
New hope for transplant patients with rare kidney disease
Disease control CompletedThis study tested a drug called pegcetacoplan in 13 adults whose rare kidney disease (C3G or IC-MPGN) came back after a kidney transplant. The goal was to see if the drug could safely reduce signs of disease in kidney tissue. Participants received the drug or standard care, and r…
Matched conditions: MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
Phase: PHASE2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 11, 2026 20:48 UTC